BWXT Announces Hurricane Helene Relief
(LYNCHBURG, Va. – Oct. 2, 2024) – BWX Technologies, Inc., the parent company of Nuclear Fuel Services (NFS), today announced a $100,000 donation to the Unicoi County United Way to support the recovery efforts underway in the Erwin, Tennessee community. This contribution will directly support emergency response teams on the ground, helping to provide essential […]
BWXT Names Gary D. Camper President of Nuclear Operations Group Subsidiary
(LYNCHBURG, Va. – Sept. 3, 2024) – BWX Technologies, Inc. (NYSE: BWXT) announced today that Gary D. Camper has been appointed president of BWXT Nuclear Operations Group, Inc. (NOG) effective Sept. 1, 2024. In this role, Camper will lead more than 5,000 employees at five sites across four states in their mission to manufacture nuclear […]
BWXT Awarded Contract to Develop Pilot Plant Solution for Domestic Uranium Enrichment
(LYNCHBURG, Va. – August 26, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced a contract from the National Nuclear Security Administration (NNSA) to complete a yearlong engineering study to evaluate options for the deployment of a centrifuge pilot plant that would establish a domestic uranium enrichment capability for national security purposes. Awarded to BWXT […]
BWXT Names Vittorio Puppo President of Medical Business
KANATA, Ontario– BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business’ mission to deliver high-quality nuclear medical products and solutions that improve patient outcomes worldwide. Puppo brings a wealth of experience to BWXT Medical, […]
BWX Technologies Reports Second Quarter 2024 Results
LYNCHBURG, Va.–(BUSINESS WIRE)–BWX Technologies, Inc. (NYSE: BWXT) (“BWXT”, “we”, “us” or the “Company”) reported second quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1. “In recent months there have been multiple important developments supporting our nuclear markets, including passage of the ADVANCE Act, federal and state legislation supporting small modular reactor […]
BWXT Medical and NorthStar Medical Radioisotopes Sign Supply Agreement Supporting Actinium-225 Production
(OTTAWA, Ontario and Beloit, WI – July 22, 2024) – BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells […]
BWXT to Evaluate Locations for Building New Nuclear TRISO Fuel Production Facility to Support Advanced Reactor Deployment
BWXT and Wyoming Energy Authority Sign Cooperation Agreement to Examine Potential Construction Options in the State (LYNCHBURG, Va. – July 18, 2024) – BWX Technologies, Inc. (NYSE: BWXT) is evaluating locations for a potential new TRISO nuclear fuel production facility to support anticipated future demand for advanced reactor deployment. As part of this effort, BWXT’s […]
BWXT Awarded Phase Two of Microreactor Evaluation Contract for State of Wyoming
(LYNCHBURG, Va. – June 17, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced the award of the second phase of a contract with the Wyoming Energy Authority to assess the viability of deploying small-scale nuclear reactors in the state as a source of resilient and reliable energy to augment existing power generation resources. Under […]
BWXT-led Team Awarded $30 Billion Management and Operating Contract for National Nuclear Security Administration’s Pantex Plant
(LYNCHBURG, Va. – June 14, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced a contract award from the U.S. Department of Energy, National Nuclear Security Administration (DOE/NNSA) for management and operations of the Pantex Plant. Following an initial term of five years, NNSA has the ability to award three additional five-year option periods. If […]
BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
(OTTAWA, Ontario – June 7, 2024) – BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient. Ac-225 is an alpha-emitting isotope used in targeted alpha therapies (TATs) that combine the isotope with specific tumor-seeking targeting vectors […]
